Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523549 · ClinicalTrials.gov registry record · Phase 4
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 229
- Enrollment target
NCT00523549 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 229 participants.
The verdict
NCT00523549, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.
Interventions
- DRUG valsartan
- DRUG amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523549
The ClinicalTrials.gov registry entry for NCT00523549 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valsartan is the first listed.
NCT00523549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523549 about?
NCT00523549 is a clinical study titled "The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction". The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties o...
What is the current status of trial NCT00523549?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 229 participants. The study started on 2006-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00523549?
The interventions under investigation include: valsartan (DRUG), amlodipine (DRUG).
Who is sponsoring clinical trial NCT00523549?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.